The Greenwall Foundation Board of Directors has renewed the contract of Michelle Groman, JD, as its President & CEO, extending through 2027 a tenure that began with her elevation into the role in July 2020.
“Since stepping into this role, Michelle has stewarded the Foundation to build on its considerable history, positioning it to reach even greater heights moving forward. This commitment to her continued leadership is indicative of our support for the work she has done and a demonstration of our assuredness that the Foundation will continue to thrive under her direction,” said Board Chair Ann Alpers, JD.
Under Ms. Groman’s leadership, the Foundation has launched two major new initiatives—Bridging Bioethics Research & Policymaking Grants and the Bernard Lo, MD Award in Bioethics—and implemented two new Strategic Priorities to guide its actions. She also oversaw a move to new offices in Washington, DC, expanded the Foundation’s communications strategy and activities, and led a celebration of the 20th anniversary of the Faculty Scholars Program.
Of the contract renewal, Ms. Groman said, “I’m honored by this vote of confidence from the Board, and eager to build on our successes over the last three years.”
Previously, Ms. Groman served as the Foundation’s Chief Operating Officer (2018-2020) and Director of Bioethics Grants, Strategy, and Special Projects (2015-2017). Prior to joining the Foundation, she was Associate Director at the Presidential Commission for the Study of Bioethical Issues where she oversaw work on diverse topics including neuroscience and related ethical issues, pediatric medical countermeasure research, and human subjects research protections.
Ms. Groman also practiced law in Washington, DC, and clerked for the Honorable Bruce M. Selya on the U.S. Court of Appeals for the First Circuit. She has published articles on a range of legal issues and topics in bioethics, including end-of-life decision-making, research ethics, and emerging genetic technologies.